Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay

Vaccine Introduction ◽

VACCINATING OLDER ADULTS IN JAPAN WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC): A COST-EFFECTIVENESS ANALYSIS

10.26226/morressier.5731f0d6d462b8029237fcb3 ◽

2016 ◽

Author(s):

Yiling Jiang

Keyword(s):

Older Adults ◽

Cost Effectiveness ◽

Conjugate Vaccine ◽

Polysaccharide Vaccine ◽

Pneumococcal Polysaccharide Vaccine ◽

VACCINATING OLDER ADULTS IN KOREA WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) OR NO VACCINATION (NOVAC): A COST-EFFECTIVENESS ANALYSIS

10.26226/morressier.5731f0d6d462b8029237fcb8 ◽

2016 ◽

Cited By ~ 1

Author(s):

Yiling Jiang

Keyword(s):

Older Adults ◽

Cost Effectiveness ◽

Conjugate Vaccine ◽

Polysaccharide Vaccine ◽

Pneumococcal Polysaccharide Vaccine ◽

Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China

Human Vaccines & Immunotherapeutics ◽

10.1080/21645515.2020.1870396 ◽

2021 ◽

pp. 1-8

Author(s):

Caixia Wang ◽

Li Su ◽

Qiuling Mu ◽

Xueyan Gu ◽

Xuejun Guo ◽

...

Keyword(s):

Cost Effectiveness ◽

Conjugate Vaccine ◽

Mainland China ◽

Effectiveness Analysis ◽

Children Under 5

PIN1 COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR HIGH RISK PATIENTS IN THE PERSPECTIVE OF BRAZILIAN NIP

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.232 ◽

2019 ◽

Vol 19 ◽

pp. S40

Author(s):

R.F. Alexandre ◽

C. Salgado De Santana ◽

T. Senna ◽

J. Spinardi ◽

R. Sini

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

Conjugate Vaccine ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Risk Patients

Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013

Vaccine ◽

10.1016/j.vaccine.2014.12.044 ◽

2015 ◽

Vol 33 ◽

pp. A182-A191 ◽

Cited By ~ 9

Author(s):

Mohammed Sibak ◽

Ibrahim Moussa ◽

Nasr El-Tantawy ◽

Shaza Badr ◽

Irtaza Chaudhri ◽

...

Keyword(s):

Cost Effectiveness ◽

Conjugate Vaccine ◽

National Immunization Program ◽

Immunization Program ◽

Effectiveness Analysis ◽

National Immunization

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

Applied Health Economics and Health Policy ◽

10.1007/s40258-018-0387-5 ◽

2018 ◽

Vol 16 (3) ◽

pp. 331-345 ◽

Cited By ~ 2

Author(s):

Lijoy Varghese ◽

Louise Talbot ◽

Andrea Govender ◽

Xu-Hao Zhang ◽

Bruce A. Mungall

Keyword(s):

New Zealand ◽

Cost Effectiveness ◽

Haemophilus Influenzae ◽

Conjugate Vaccine ◽

Mass Vaccination ◽

Effectiveness Analysis ◽

Universal Mass Vaccination

Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia

BMC Infectious Diseases ◽

10.1186/1471-2334-14-172 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 13

Author(s):

Jaime E Ordóñez ◽

John J Orozco

Keyword(s):

Older Adults ◽

Cost Effectiveness ◽

Conjugate Vaccine ◽

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

The European Journal of Health Economics ◽

10.1007/s10198-008-0098-1 ◽

2008 ◽

Vol 10 (1) ◽

pp. 25-38 ◽

Cited By ~ 25

Author(s):

Christa Claes ◽

Ralf René Reinert ◽

Johann-Matthias Graf von der Schulenburg

Keyword(s):

Cost Effectiveness ◽

Conjugate Vaccine ◽

Herd Immunity ◽

Heptavalent Pneumococcal Conjugate Vaccine

Effectiveness Analysis ◽

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

Scandinavian Journal of Infectious Diseases ◽

10.1080/00365540802014872 ◽

2008 ◽

Vol 40 (9) ◽

pp. 721-729 ◽

Cited By ~ 22

Author(s):

Annika Bergman ◽

Jonas Hjelmgren ◽

Åke Örtqvist ◽

Torbjørn Wisløff ◽

Ivar Sønbø Kristiansen ◽

...

Keyword(s):

Cost Effectiveness ◽

Conjugate Vaccine ◽

Vaccination Programme ◽

Universal Vaccination ◽

A Cost-Effectiveness Analysis of Vaccinating The Elderly with The 23-Valent Pneumococcal Polysaccharide Vaccine (Ppv23) Compared To No Vaccination, The 13-Valent Pneumococcal Conjugate Vaccine (Pcv13), or Pcv13 Followed by Ppv23 in Brazil

Value in Health ◽

10.1016/j.jval.2017.08.2909 ◽

2017 ◽

Vol 20 (9) ◽

pp. A930 ◽

Cited By ~ 1

Author(s):

Y Jiang ◽

X Yang ◽

T Petigara ◽

L Chabrol Haas ◽

J Graham

Keyword(s):

Cost Effectiveness ◽

Conjugate Vaccine ◽

The Elderly ◽

Polysaccharide Vaccine ◽

Pneumococcal Polysaccharide Vaccine ◽